RPID: Rapid Micro Biosystems, Inc. EV/EBITDA Multiple

This EV/EBITDA valuation chart for Rapid Micro Biosystems (RPID), a developer of microbiology control systems, reflects a value of 0.00. The company's business moat is supported by unique patents and strict FDA oversight. Mandatory drug safety requirements ensure a stable cash flow, reducing dependence on market cycles. Demand is rising as major B2B clients transition to automated platforms to accelerate the release of sterile products.

Rapid Micro - RPID Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for rapidmicrobio.com (RPID)

- stock price and consensus target price:

Stock Quotes Rapid Micro Biosystems, Inc.|RPID - Analyst Forecast Prices

- market capitalization information:

Market Capitalization Rapid Micro Biosystems, Inc.|RPID - Company Buyout Price

- issuer book value statistics:

Book Value per Share Rapid Micro Biosystems|RPID - Company Net Assets|Market Cap to Net Assets Ratio rapidmicrobio.com|RPID - Aggregate Asset Value

- company liabilities and liquidity data:

Debt to Equity Rapid Micro Biosystems|RPID - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Rapid Micro Biosystems, Inc.|RPID - Company Cumulative Debt|Debts to Book Capitalization Rapid Micro Biosystems, Inc.|RPID - Company Long-Term Indebtedness|Company Short-Term Debts Rapid Micro Biosystems|Quick Ratio rapidmicrobio.com

- financial results and valuation multiples details:

RPID - Net Income|Projected Future Earnings Rapid Micro Biosystems|RPID - P/E Multiple|Future Price to Earnings Rapid Micro Biosystems, Inc.|RPID - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Rapid Micro Biosystems, Inc.|RPID - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Rapid Micro Biosystems|RPID - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months rapidmicrobio.com|RPID - Net earnings per share change in current year|Expected earnings per share growth for next year Rapid Micro Biosystems

Initial company analysis:Rapid Micro RPID

Investors must identify the fundamental drivers of capital resilience during periods of market volatility. This indicator compares the total enterprise value, including net debt, with operating profit before interest, taxes, depreciation, and amortization. The EV/EBITDA multiple trend clearly demonstrates the company's margin of safety in the face of a recession. For Rapid Micro Biosystems (RPID), this confirms the effectiveness of management's strategy to increase the share of recurring subscriptions within the pharmaceutical industry.

Competitor analysis for Rapid Micro Biosystems

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Techne Corp|Enterprise Value to EBITDA Ratio BRKR|AZTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Varex Imaging (VREX)|Enterprise Value to EBITDA Ratio semlerscientific.com SMLR|EV/EBITDA Multiple BFLY (Butterfly Network)|Mesa Laboratories Inc (MLAB) - Company Value to EBITDA|Quantum-Si Corp - EV/EBITDA Multiple|NNOX (Nano-X Imaging Ltd) - Enterprise Value to Operating Income Before Depreciation|QTRX: EV/EBITDA Multiple|MASS - Total Company Value to Operating Income Before Depreciation Ratio|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MaxCyte Inc. (MXCT)|EV/EBITDA Multiple SEER|EV/EBITDA Multiple Hyperfine Medical (HYPR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FONAR Corporation FONR|Daxor Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDAI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIVS (Organovo Holdings)|ACON: EV/EBITDA Multiple|Company Value to EBITDA Akoya Biosciences, Inc. (AKYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ThermoGenesis|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems)